Design of embedded chimeric peptide nucleic acids that efficiently enter and accurately reactivate gene expression in vivo

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 39, 2010, Pages 16846-16851

  Chen, Joy ^a   Peterson, Kenneth R ^b   Iancu Rubin, Camelia ^a   Bieker, James J ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

globin gene reactivation

Indexed keywords

GAMMA GLOBIN; PEPTIDE NUCLEIC ACID; HEMOGLOBIN GAMMA CHAIN;

ANIMAL CELL; ARTICLE; DNA BINDING; DRUG DESIGN; DRUG TARGETING; GENE ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; TRANSCRIPTION INITIATION; TRANSGENIC MOUSE; ANIMAL; BONE MARROW CELL; CELL CULTURE; CELL LINE; CELL NUCLEUS; CHEMISTRY; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; GENETICS; HEMOGLOBINOPATHIES; METABOLISM; MOUSE;

MUS MUSCULUS;

ANIMALS; BONE MARROW CELLS; CELL LINE; CELL NUCLEUS; CELLS, CULTURED; CHROMATIN IMMUNOPRECIPITATION; DRUG DESIGN; GAMMA-GLOBINS; GENE EXPRESSION; HEMOGLOBINOPATHIES; HUMANS; MICE; PEPTIDE NUCLEIC ACIDS; PROMOTER REGIONS, GENETIC;

EID: 78049256781     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0912896107     Document Type: Article

References (40)

1. Davidson EH (1986) Gene Activity in Early Development (Academic, Orlando, FL), 3rd Ed.
2. Bresnick EH, Martowicz ML, Pal S, Johnson KD (2005) Developmental control via GATA factor interplay at chromatin domains. J Cell Physiol 205(1):1-9. (Pubitemid 41262845)
3. Noordermeer D, de Laat W (2008) Joining the loops: ß-globin gene regulation. IUBMB Life 60:824-833.
4. Krumlauf R (1994) Hox genes in vertebrate development. Cell 78:191-201.
5. Stamatoyannopoulos G (2001) The Molecular Basis of Blood Diseases, eds G Stamatoyannopoulos, PW Majerus, RM Perlmutter, and H Varmus (Saunders, Philadelphia), 3rd Ed.
6. Schechter AN (2008) Hemoglobin research and the origins of molecular medicine. Blood 112:3927-3938.
7. Weatherall DJ (1994) The thalassemias. The Molecular Bases of Blood Diseases, eds G Stamatoyannopoulos, AWNienhuis, PW Majerus, and H Varmus (Saunders, Philadelphia), pp 157-205.
8. Bunn HF (1994) Sickle hemoglobin and other hemoglobin mutants. The Molecular Bases of Blood Diseases, eds G Stamatoyannopoulos, AW Nienhuis, PW Majerus, and H Varmus (Saunders, Philadelphia), pp 207-256.
9. Atweh GF, Schechter AN (2001) Pharmacologic induction of fetal hemoglobin: Raising the therapeutic bar in sickle cell disease. Curr Opin Hematol 8:123-130. (Pubitemid 32207561)
10. Nielsen PE, Egholm M, Berg RH, Buchardt O (1991) Sequence-selective recognition of DNA by strand displacement with a thymine-substituted polyamide. Science 254:1497-1500. (Pubitemid 21917487)
11. Kaihatsu K, Janowski BA, Corey DR (2004) Recognition of chromosomal DNA by PNAs. Chem Biol 11:749-758.
12. Pooga M, Land T, Bartfai T, Langel U (2001) PNA oligomers as tools for specific modulation of gene expression. Biomol Eng 17:183-192. (Pubitemid 32416455)
13. Zhang X, Ishihara T, Corey DR (2000) Strand invasion by mixed base PNAs and a PNA-peptide chimera. Nucleic Acids Res 28:3332-3338. (Pubitemid 30662298)
14. Nielsen PE (2001) Peptide nucleic acids as antibacterial agents via the antisense principle. Expert Opin Inv Drug 10:331-341.
15. Cutrona G, et al. (2000) Effects in live cells of a c-myc anti-gene PNA linked to a nuclear localization signal. Nat Biotechnol 18:300-303. (Pubitemid 30159481)
16. Hu J, et al. (2009) Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs. Nat Biotechnol 27:478-484.
17. Nielsen PE (2004) PNA Technology. Mol Biotechnol 26:233-248.
18. Nielsen PE (2005) Addressing the challenges of cellular delivery and bioavailability of peptide nucleic acids (PNA). Q Rev Biophys 38:345-350.
19. Braun K, et al. (2002) A biological transporter for the delivery of peptide nucleic acids (PNAs) to the nuclear compartment of living cells. J Mol Biol 318:237-243. (Pubitemid 34734822)
20. Bentin T, Hansen GI, Nielsen PE (2002) Measurement of PNA binding to doublestranded DNA. Method Mol Biol 208:91-109.
21. Nielsen PE (2001) Peptide nucleic acid: A versatile tool in genetic diagnostics and molecular biology. Curr Opin Biotechnol 12:16-20.
22. Sei S, et al. (2000) Identification of a key target sequence to block human immunodeficiency virus type 1 replication within the gag-pol transframe domain. J Virol 74:4621-4633. (Pubitemid 30237887)
23. Stamatoyannopoulos JA, Nienhuis AW(1992) Therapeutic approaches to hemoglobin switching in treatment of hemoglobinopathies. Annu Rev Med 43:497-521.
24. Wadia JS, Stan RV, Dowdy SF (2004) Transducible TAT-HA fusogenic peptide enhances escape of TAT-fusion proteins after lipid raft macropinocytosis. Nat Med 10:310-315.
25. Kaplan IM, Wadia JS, Dowdy SF (2005) Cationic TAT peptide transduction domain enters cells by macropinocytosis. J Control Release 102:247-253.
26. Snyder EL, Meade BR, Saenz CC, Dowdy SF (2004) Treatment of terminal peritoneal carcinomatosis by a transducible p53-activating peptide. PLoS Biol 2:E36.
27. Ansari AZ, Mapp AK, Nguyen DH, Dervan PB, Ptashne M (2001) Towards a minimal motif for artificial transcriptional activators. Chem Biol 8:583-592.
28. Arora PS, Ansari AZ, Best TP, Ptashne M, Dervan PB (2002) Design of artificial transcriptional activators with rigid poly-L-proline linkers. J Am Chem Soc 124:13067-13071. (Pubitemid 35247118)
29. Blau CA, et al. (2005) γ-Globin gene expression in chemical inducer of dimerization (CID)-dependent multipotential cells established from human β-globin locus yeast artificial chromosome (β-YAC) transgenic mice. J Biol Chem 280:36642-36647.
30. Peterson KR, et al. (1993) Use of yeast artificial chromosomes (YACs) for studying control of gene expression: Correct regulation of the genes of a human beta-globin locus YAC following transfer to mouse erythroleukemia cell lines. Proc Natl Acad Sci USA 90:11207-11211.
31. Stanojevic D, Young RA (2002) A highly potent artificial transcription factor. Biochemistry 41:7209-7216. (Pubitemid 34602436)
32. Saar K, et al. (2005) Cell-penetrating peptides: A comparative membrane toxicity study. Anal Biochem 345:55-65. (Pubitemid 41558194)
33. Chaubey B, Tripathi S, Pandey VN (2008) Single acute-dose and repeat-doses toxicity of anti-HIV-1 PNA TAR-penetratin conjugate after intraperitoneal administration to mice. Oligonucleotides 18:9-20.
34. Upadhyay A, Ponzio NM, Pandey VN (2008) Immunological response to peptide nucleic acid and its peptide conjugate targeted to transactivation response (TAR) region of HIV-1 RNA genome. Oligonucleotides 18:329-335. (Pubitemid 352791343)
35. Platt OS, et al. (1994) Mortality in sickle cell disease. Life expectancy and risk factors for early death. N Engl J Med 330:1639-1644.
36. Noguchi CT, Rodgers GP, Serjeant G, Schechter AN (1988) Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N Engl J Med 318:96-99. (Pubitemid 18029302)
37. Atweh GF, et al. (1999) Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood 93:1790-1797.
38. Wang G, et al. (1999) Peptide nucleic acid (PNA) binding-mediated induction of human gamma-globin gene expression. Nucleic Acids Res 27:2806-2813. (Pubitemid 29306581)
39. Lohmann F, Bieker JJ (2008) Activation of Eklf expression during hematopoiesis by Gata2 and Smad5 prior to erythroid commitment. Development 135:2071-2082. (Pubitemid 352022521)
40. Viens A, Mechold U, Lehrmann H, Harel-Bellan A, Ogryzko V (2004) Use of protein biotinylation in vivo for chromatin immunoprecipitation. Anal Biochem 325:68-76. (Pubitemid 38050268)